nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Topotecan—lung cancer	0.0561	0.142	CbGbCtD
Maraviroc—CYP3A4—Gefitinib—lung cancer	0.0513	0.13	CbGbCtD
Maraviroc—CYP3A4—Teniposide—lung cancer	0.0497	0.126	CbGbCtD
Maraviroc—CYP3A4—Vinorelbine—lung cancer	0.0395	0.1	CbGbCtD
Maraviroc—CYP3A4—Crizotinib—lung cancer	0.0314	0.0796	CbGbCtD
Maraviroc—CYP3A4—Erlotinib—lung cancer	0.0303	0.0768	CbGbCtD
Maraviroc—CYP3A4—Paclitaxel—lung cancer	0.0278	0.0703	CbGbCtD
Maraviroc—CYP3A4—Irinotecan—lung cancer	0.0274	0.0694	CbGbCtD
Maraviroc—CYP3A4—Vinblastine—lung cancer	0.0243	0.0617	CbGbCtD
Maraviroc—CYP3A4—Etoposide—lung cancer	0.0219	0.0556	CbGbCtD
Maraviroc—CYP3A4—Docetaxel—lung cancer	0.0201	0.0508	CbGbCtD
Maraviroc—CYP3A4—Doxorubicin—lung cancer	0.015	0.0379	CbGbCtD
Maraviroc—CCR5—respiratory system—lung cancer	0.0057	0.528	CbGeAlD
Maraviroc—CCR5—lung—lung cancer	0.00303	0.28	CbGeAlD
Maraviroc—CCR5—lymph node—lung cancer	0.00207	0.192	CbGeAlD
Maraviroc—CCR5—Disease—NPPA—lung cancer	0.00034	0.00182	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—DUSP3—lung cancer	0.000338	0.00181	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—APP—lung cancer	0.000337	0.0018	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—lung cancer	0.000332	0.00178	CbGpPWpGaD
Maraviroc—CCR5—Disease—PPIA—lung cancer	0.000332	0.00178	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RHEB—lung cancer	0.000332	0.00178	CbGpPWpGaD
Maraviroc—CCR5—Disease—ALDOA—lung cancer	0.00033	0.00176	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—ANXA1—lung cancer	0.000322	0.00173	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GRM8—lung cancer	0.000314	0.00168	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000313	0.00167	CbGpPWpGaD
Maraviroc—CCR5—Disease—ADCY1—lung cancer	0.000311	0.00167	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—POMC—lung cancer	0.000308	0.00165	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—APP—lung cancer	0.000306	0.00164	CbGpPWpGaD
Maraviroc—CCR5—Disease—ENO2—lung cancer	0.000305	0.00163	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SKI—lung cancer	0.000304	0.00163	CbGpPWpGaD
Maraviroc—CCR5—Disease—PPP2R1B—lung cancer	0.000303	0.00162	CbGpPWpGaD
Maraviroc—CCR5—Disease—SMARCA4—lung cancer	0.000303	0.00162	CbGpPWpGaD
Maraviroc—CCR5—Disease—ENO1—lung cancer	0.000277	0.00148	CbGpPWpGaD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	0.000272	0.00146	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PXN—lung cancer	0.000264	0.00142	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AVP—lung cancer	0.000262	0.0014	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP2E1—lung cancer	0.000261	0.0014	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—lung cancer	0.000259	0.00139	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GRP—lung cancer	0.000259	0.00139	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—OXTR—lung cancer	0.000259	0.00139	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKR1C1—lung cancer	0.000259	0.00139	CbGpPWpGaD
Maraviroc—CCR5—Disease—APP—lung cancer	0.000258	0.00138	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGF9—lung cancer	0.000256	0.00137	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.000248	0.00133	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000245	0.00131	CbGpPWpGaD
Maraviroc—CCR5—Disease—JUNB—lung cancer	0.000244	0.00131	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GNG11—lung cancer	0.000242	0.0013	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL8—lung cancer	0.000238	0.00127	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AVP—lung cancer	0.000238	0.00127	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFC—lung cancer	0.000231	0.00124	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ADCY1—lung cancer	0.000218	0.00117	CbGpPWpGaD
Maraviroc—CCR5—Disease—FOXO3—lung cancer	0.000214	0.00115	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SMARCA4—lung cancer	0.000212	0.00114	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PPP2R1B—lung cancer	0.000212	0.00114	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	0.000211	0.00113	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CAT—lung cancer	0.000209	0.00112	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—lung cancer	0.000208	0.00111	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HSPB1—lung cancer	0.000205	0.0011	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM2—lung cancer	0.000203	0.00109	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CNDP2—lung cancer	0.000203	0.00109	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTHLH—lung cancer	0.000203	0.00108	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	0.000201	0.00108	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM2—lung cancer	0.000201	0.00107	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ANXA1—lung cancer	0.00019	0.00102	CbGpPWpGaD
Maraviroc—CCR5—Disease—HES1—lung cancer	0.00019	0.00102	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP1A1—lung cancer	0.000187	0.001	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FLT1—lung cancer	0.000184	0.000988	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP2A7—lung cancer	0.000184	0.000984	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CG—lung cancer	0.000183	0.000978	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2A7—lung cancer	0.000181	0.000971	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH3—lung cancer	0.000181	0.000967	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APP—lung cancer	0.000181	0.000967	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGF9—lung cancer	0.000179	0.000959	CbGpPWpGaD
Maraviroc—CCR5—Disease—ERCC2—lung cancer	0.000177	0.000949	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—POMC—lung cancer	0.000174	0.000931	CbGpPWpGaD
Maraviroc—CCR5—Disease—ERBB3—lung cancer	0.000173	0.000928	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JUNB—lung cancer	0.000171	0.000915	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	0.000171	0.000915	CbGpPWpGaD
Maraviroc—CCR5—Disease—TERT—lung cancer	0.000166	0.00089	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CG—lung cancer	0.000166	0.000888	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA3—lung cancer	0.000164	0.000877	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTA3—lung cancer	0.000162	0.000865	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGFR1—lung cancer	0.000161	0.000864	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CD—lung cancer	0.000161	0.00086	CbGpPWpGaD
Maraviroc—CCR5—Disease—HIF1A—lung cancer	0.000159	0.000851	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—POMC—lung cancer	0.000158	0.000846	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STK11—lung cancer	0.000155	0.000831	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6R—lung cancer	0.000154	0.000825	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOA1—lung cancer	0.000153	0.000821	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000151	0.000811	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA4—lung cancer	0.00015	0.000802	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FOXO3—lung cancer	0.00015	0.000802	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.00015	0.0008	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTA4—lung cancer	0.000148	0.000791	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAP2K1—lung cancer	0.000147	0.000786	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA2—lung cancer	0.000146	0.000782	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CD—lung cancer	0.000146	0.000781	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA1—lung cancer	0.000141	0.000754	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AVP—lung cancer	0.00014	0.000752	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CB—lung cancer	0.00014	0.00075	CbGpPWpGaD
Maraviroc—CCR5—Disease—APC—lung cancer	0.00014	0.00075	CbGpPWpGaD
Maraviroc—CCR5—Disease—KIT—lung cancer	0.00014	0.00075	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGF—lung cancer	0.000138	0.000741	CbGpPWpGaD
Maraviroc—Shock—Paclitaxel—lung cancer	0.000138	0.000339	CcSEcCtD
Maraviroc—Dizziness—Vinorelbine—lung cancer	0.000138	0.000339	CcSEcCtD
Maraviroc—Orthostatic hypotension—Doxorubicin—lung cancer	0.000138	0.000339	CcSEcCtD
Maraviroc—Abdominal pain upper—Doxorubicin—lung cancer	0.000138	0.000339	CcSEcCtD
Maraviroc—Nervous system disorder—Paclitaxel—lung cancer	0.000138	0.000338	CcSEcCtD
Maraviroc—Breast disorder—Doxorubicin—lung cancer	0.000137	0.000335	CcSEcCtD
Maraviroc—Anorexia—Etoposide—lung cancer	0.000137	0.000335	CcSEcCtD
Maraviroc—Skin disorder—Paclitaxel—lung cancer	0.000136	0.000335	CcSEcCtD
Maraviroc—Body temperature increased—Irinotecan—lung cancer	0.000136	0.000334	CcSEcCtD
Maraviroc—Abdominal pain—Irinotecan—lung cancer	0.000136	0.000334	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.000136	0.000334	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Doxorubicin—lung cancer	0.000136	0.000334	CcSEcCtD
Maraviroc—Decreased appetite—Cisplatin—lung cancer	0.000136	0.000334	CcSEcCtD
Maraviroc—Pneumonia—Methotrexate—lung cancer	0.000135	0.000332	CcSEcCtD
Maraviroc—Nasopharyngitis—Doxorubicin—lung cancer	0.000135	0.000332	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IGF1R—lung cancer	0.000135	0.000724	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Cisplatin—lung cancer	0.000135	0.000331	CcSEcCtD
Maraviroc—Anaemia—Docetaxel—lung cancer	0.000135	0.000331	CcSEcCtD
Maraviroc—Infestation NOS—Methotrexate—lung cancer	0.000135	0.00033	CcSEcCtD
Maraviroc—Infestation—Methotrexate—lung cancer	0.000135	0.00033	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CXCL8—lung cancer	0.000135	0.00072	CbGpPWpGaD
Maraviroc—Depression—Methotrexate—lung cancer	0.000134	0.000329	CcSEcCtD
Maraviroc—Anorexia—Paclitaxel—lung cancer	0.000134	0.000328	CcSEcCtD
Maraviroc—Pain—Cisplatin—lung cancer	0.000134	0.000328	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Methotrexate—lung cancer	0.000133	0.000327	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000133	0.000327	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—AKR1C1—lung cancer	0.000133	0.000713	CbGpPWpGaD
Maraviroc—Vomiting—Vinorelbine—lung cancer	0.000133	0.000326	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HES1—lung cancer	0.000133	0.000711	CbGpPWpGaD
Maraviroc—Body temperature increased—Gemcitabine—lung cancer	0.000133	0.000325	CcSEcCtD
Maraviroc—Renal failure—Methotrexate—lung cancer	0.000132	0.000324	CcSEcCtD
Maraviroc—Rash—Vinorelbine—lung cancer	0.000132	0.000323	CcSEcCtD
Maraviroc—Dermatitis—Vinorelbine—lung cancer	0.000132	0.000323	CcSEcCtD
Maraviroc—CCR5—Disease—BRAF—lung cancer	0.000132	0.000705	CbGpPWpGaD
Maraviroc—Abdominal distension—Doxorubicin—lung cancer	0.000132	0.000323	CcSEcCtD
Maraviroc—Stomatitis—Methotrexate—lung cancer	0.000131	0.000322	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—UGT1A1—lung cancer	0.000131	0.000701	CbGpPWpGaD
Maraviroc—Headache—Vinorelbine—lung cancer	0.000131	0.000321	CcSEcCtD
Maraviroc—Syncope—Docetaxel—lung cancer	0.000131	0.000321	CcSEcCtD
Maraviroc—Conjunctivitis—Methotrexate—lung cancer	0.000131	0.000321	CcSEcCtD
Maraviroc—Influenza—Doxorubicin—lung cancer	0.000131	0.000321	CcSEcCtD
Maraviroc—Leukopenia—Docetaxel—lung cancer	0.000131	0.00032	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—RAF1—lung cancer	0.00013	0.000697	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6R—lung cancer	0.00013	0.000696	CbGpPWpGaD
Maraviroc—CCR5—Disease—CREBBP—lung cancer	0.00013	0.000695	CbGpPWpGaD
Maraviroc—Eosinophilia—Doxorubicin—lung cancer	0.000129	0.000317	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—UGT1A1—lung cancer	0.000129	0.000692	CbGpPWpGaD
Maraviroc—Paraesthesia—Etoposide—lung cancer	0.000129	0.000316	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—IL2—lung cancer	0.000129	0.000689	CbGpPWpGaD
Maraviroc—Loss of consciousness—Docetaxel—lung cancer	0.000128	0.000315	CcSEcCtD
Maraviroc—Pancreatitis—Doxorubicin—lung cancer	0.000128	0.000314	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000128	0.000314	CcSEcCtD
Maraviroc—Cough—Docetaxel—lung cancer	0.000127	0.000312	CcSEcCtD
Maraviroc—Angina pectoris—Doxorubicin—lung cancer	0.000127	0.000312	CcSEcCtD
Maraviroc—Hepatobiliary disease—Methotrexate—lung cancer	0.000127	0.000312	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CB—lung cancer	0.000127	0.000681	CbGpPWpGaD
Maraviroc—Insomnia—Paclitaxel—lung cancer	0.000127	0.000312	CcSEcCtD
Maraviroc—Hypersensitivity—Irinotecan—lung cancer	0.000127	0.000311	CcSEcCtD
Maraviroc—Convulsion—Docetaxel—lung cancer	0.000126	0.00031	CcSEcCtD
Maraviroc—Paraesthesia—Paclitaxel—lung cancer	0.000126	0.000309	CcSEcCtD
Maraviroc—Bronchitis—Doxorubicin—lung cancer	0.000126	0.000308	CcSEcCtD
Maraviroc—Agranulocytosis—Methotrexate—lung cancer	0.000126	0.000308	CcSEcCtD
Maraviroc—Decreased appetite—Etoposide—lung cancer	0.000125	0.000306	CcSEcCtD
Maraviroc—Myalgia—Docetaxel—lung cancer	0.000124	0.000305	CcSEcCtD
Maraviroc—Pancytopenia—Doxorubicin—lung cancer	0.000124	0.000304	CcSEcCtD
Maraviroc—Nausea—Vinorelbine—lung cancer	0.000124	0.000304	CcSEcCtD
Maraviroc—CCR5—Disease—MAP2K1—lung cancer	0.000124	0.000663	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Etoposide—lung cancer	0.000124	0.000303	CcSEcCtD
Maraviroc—Body temperature increased—Cisplatin—lung cancer	0.000124	0.000303	CcSEcCtD
Maraviroc—Asthenia—Irinotecan—lung cancer	0.000124	0.000303	CcSEcCtD
Maraviroc—Fatigue—Etoposide—lung cancer	0.000124	0.000303	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000123	0.000303	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CD—lung cancer	0.000123	0.000659	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000123	0.000658	CbGpPWpGaD
Maraviroc—Pain—Etoposide—lung cancer	0.000123	0.000301	CcSEcCtD
Maraviroc—Constipation—Etoposide—lung cancer	0.000123	0.000301	CcSEcCtD
Maraviroc—Neutropenia—Doxorubicin—lung cancer	0.000122	0.0003	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCL8—lung cancer	0.000122	0.000654	CbGpPWpGaD
Maraviroc—Decreased appetite—Paclitaxel—lung cancer	0.000122	0.0003	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000121	0.000298	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ERBB3—lung cancer	0.000121	0.00065	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000121	0.000298	CcSEcCtD
Maraviroc—Fatigue—Paclitaxel—lung cancer	0.000121	0.000297	CcSEcCtD
Maraviroc—Asthenia—Gemcitabine—lung cancer	0.00012	0.000295	CcSEcCtD
Maraviroc—Constipation—Paclitaxel—lung cancer	0.00012	0.000295	CcSEcCtD
Maraviroc—Pain—Paclitaxel—lung cancer	0.00012	0.000295	CcSEcCtD
Maraviroc—Pharyngitis—Methotrexate—lung cancer	0.00012	0.000294	CcSEcCtD
Maraviroc—Urinary tract disorder—Methotrexate—lung cancer	0.000119	0.000293	CcSEcCtD
Maraviroc—Oedema—Docetaxel—lung cancer	0.000119	0.000292	CcSEcCtD
Maraviroc—Pruritus—Gemcitabine—lung cancer	0.000119	0.000291	CcSEcCtD
Maraviroc—Urethral disorder—Methotrexate—lung cancer	0.000118	0.00029	CcSEcCtD
Maraviroc—Infection—Docetaxel—lung cancer	0.000118	0.00029	CcSEcCtD
Maraviroc—Diarrhoea—Irinotecan—lung cancer	0.000118	0.000289	CcSEcCtD
Maraviroc—Pneumonia—Doxorubicin—lung cancer	0.000117	0.000287	CcSEcCtD
Maraviroc—Gastrointestinal pain—Etoposide—lung cancer	0.000117	0.000287	CcSEcCtD
Maraviroc—Shock—Docetaxel—lung cancer	0.000117	0.000287	CcSEcCtD
Maraviroc—Nervous system disorder—Docetaxel—lung cancer	0.000117	0.000286	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—IL2—lung cancer	0.000117	0.000625	CbGpPWpGaD
Maraviroc—Infestation—Doxorubicin—lung cancer	0.000117	0.000286	CcSEcCtD
Maraviroc—Infestation NOS—Doxorubicin—lung cancer	0.000117	0.000286	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TERT—lung cancer	0.000116	0.000623	CbGpPWpGaD
Maraviroc—Skin disorder—Docetaxel—lung cancer	0.000116	0.000284	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—MDM2—lung cancer	0.000116	0.000619	CbGpPWpGaD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—lung cancer	0.000116	0.000283	CcSEcCtD
Maraviroc—Hypersensitivity—Cisplatin—lung cancer	0.000115	0.000283	CcSEcCtD
Maraviroc—Gastrointestinal pain—Paclitaxel—lung cancer	0.000115	0.000282	CcSEcCtD
Maraviroc—Diarrhoea—Gemcitabine—lung cancer	0.000115	0.000282	CcSEcCtD
Maraviroc—Renal failure—Doxorubicin—lung cancer	0.000115	0.000281	CcSEcCtD
Maraviroc—Erythema multiforme—Methotrexate—lung cancer	0.000114	0.00028	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—lung cancer	0.000114	0.00028	CcSEcCtD
Maraviroc—Dizziness—Irinotecan—lung cancer	0.000114	0.000279	CcSEcCtD
Maraviroc—Jaundice—Doxorubicin—lung cancer	0.000114	0.000279	CcSEcCtD
Maraviroc—Stomatitis—Doxorubicin—lung cancer	0.000114	0.000279	CcSEcCtD
Maraviroc—Anorexia—Docetaxel—lung cancer	0.000114	0.000278	CcSEcCtD
Maraviroc—Abdominal pain—Etoposide—lung cancer	0.000113	0.000278	CcSEcCtD
Maraviroc—Body temperature increased—Etoposide—lung cancer	0.000113	0.000278	CcSEcCtD
Maraviroc—Conjunctivitis—Doxorubicin—lung cancer	0.000113	0.000278	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FGFR1—lung cancer	0.000113	0.000605	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000113	0.000605	CbGpPWpGaD
Maraviroc—Eye disorder—Methotrexate—lung cancer	0.000113	0.000277	CcSEcCtD
Maraviroc—Asthenia—Cisplatin—lung cancer	0.000112	0.000275	CcSEcCtD
Maraviroc—Cardiac disorder—Methotrexate—lung cancer	0.000112	0.000275	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—HPGDS—lung cancer	0.000111	0.000596	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HIF1A—lung cancer	0.000111	0.000596	CbGpPWpGaD
Maraviroc—Abdominal pain—Paclitaxel—lung cancer	0.000111	0.000272	CcSEcCtD
Maraviroc—Body temperature increased—Paclitaxel—lung cancer	0.000111	0.000272	CcSEcCtD
Maraviroc—CCR5—Disease—MDM2—lung cancer	0.00011	0.00059	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Doxorubicin—lung cancer	0.00011	0.00027	CcSEcCtD
Maraviroc—CCR5—Disease—RAF1—lung cancer	0.00011	0.000588	CbGpPWpGaD
Maraviroc—Angiopathy—Methotrexate—lung cancer	0.00011	0.000269	CcSEcCtD
Maraviroc—Vomiting—Irinotecan—lung cancer	0.00011	0.000269	CcSEcCtD
Maraviroc—Sinusitis—Doxorubicin—lung cancer	0.000109	0.000268	CcSEcCtD
Maraviroc—Mediastinal disorder—Methotrexate—lung cancer	0.000109	0.000267	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—lung cancer	0.000109	0.000267	CcSEcCtD
Maraviroc—CCR5—Disease—ERBB2—lung cancer	0.000109	0.000582	CbGpPWpGaD
Maraviroc—Rash—Irinotecan—lung cancer	0.000109	0.000266	CcSEcCtD
Maraviroc—Dermatitis—Irinotecan—lung cancer	0.000109	0.000266	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000109	0.000266	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTT1—lung cancer	0.000108	0.000578	CbGpPWpGaD
Maraviroc—Headache—Irinotecan—lung cancer	0.000108	0.000265	CcSEcCtD
Maraviroc—Insomnia—Docetaxel—lung cancer	0.000108	0.000264	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APOA1—lung cancer	0.000107	0.000575	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CB—lung cancer	0.000107	0.000574	CbGpPWpGaD
Maraviroc—CCR5—Disease—MTOR—lung cancer	0.000107	0.000574	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD4—lung cancer	0.000107	0.000573	CbGpPWpGaD
Maraviroc—Diarrhoea—Cisplatin—lung cancer	0.000107	0.000263	CcSEcCtD
Maraviroc—Paraesthesia—Docetaxel—lung cancer	0.000107	0.000262	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP2A6—lung cancer	0.000107	0.000572	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GCLC—lung cancer	0.000107	0.000572	CbGpPWpGaD
Maraviroc—Alopecia—Methotrexate—lung cancer	0.000107	0.000262	CcSEcCtD
Maraviroc—Vomiting—Gemcitabine—lung cancer	0.000107	0.000262	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KDR—lung cancer	0.000106	0.00057	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—lung cancer	0.000106	0.000569	CbGpPWpGaD
Maraviroc—Mental disorder—Methotrexate—lung cancer	0.000106	0.00026	CcSEcCtD
Maraviroc—Rash—Gemcitabine—lung cancer	0.000106	0.00026	CcSEcCtD
Maraviroc—Dermatitis—Gemcitabine—lung cancer	0.000106	0.000259	CcSEcCtD
Maraviroc—Hypersensitivity—Etoposide—lung cancer	0.000106	0.000259	CcSEcCtD
Maraviroc—Erythema—Methotrexate—lung cancer	0.000105	0.000258	CcSEcCtD
Maraviroc—Malnutrition—Methotrexate—lung cancer	0.000105	0.000258	CcSEcCtD
Maraviroc—Headache—Gemcitabine—lung cancer	0.000105	0.000258	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—lung cancer	0.000105	0.000257	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—lung cancer	0.000104	0.000255	CcSEcCtD
Maraviroc—Decreased appetite—Docetaxel—lung cancer	0.000104	0.000254	CcSEcCtD
Maraviroc—Hypersensitivity—Paclitaxel—lung cancer	0.000104	0.000254	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—lung cancer	0.000103	0.000253	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Docetaxel—lung cancer	0.000103	0.000252	CcSEcCtD
Maraviroc—Asthenia—Etoposide—lung cancer	0.000103	0.000252	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—lung cancer	0.000103	0.000252	CcSEcCtD
Maraviroc—Fatigue—Docetaxel—lung cancer	0.000103	0.000252	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—lung cancer	0.000103	0.000252	CcSEcCtD
Maraviroc—Nausea—Irinotecan—lung cancer	0.000102	0.000251	CcSEcCtD
Maraviroc—Pain—Docetaxel—lung cancer	0.000102	0.00025	CcSEcCtD
Maraviroc—Constipation—Docetaxel—lung cancer	0.000102	0.00025	CcSEcCtD
Maraviroc—Pruritus—Etoposide—lung cancer	0.000101	0.000249	CcSEcCtD
Maraviroc—Asthenia—Paclitaxel—lung cancer	0.000101	0.000247	CcSEcCtD
Maraviroc—Nausea—Gemcitabine—lung cancer	9.97e-05	0.000244	CcSEcCtD
Maraviroc—Vomiting—Cisplatin—lung cancer	9.95e-05	0.000244	CcSEcCtD
Maraviroc—Pruritus—Paclitaxel—lung cancer	9.94e-05	0.000244	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—lung cancer	9.89e-05	0.000243	CcSEcCtD
Maraviroc—Rash—Cisplatin—lung cancer	9.86e-05	0.000242	CcSEcCtD
Maraviroc—Dermatitis—Cisplatin—lung cancer	9.85e-05	0.000242	CcSEcCtD
Maraviroc—Diarrhoea—Etoposide—lung cancer	9.81e-05	0.00024	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KIT—lung cancer	9.8e-05	0.000525	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APC—lung cancer	9.8e-05	0.000525	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—lung cancer	9.8e-05	0.000525	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—NRAS—lung cancer	9.8e-05	0.000525	CbGpPWpGaD
Maraviroc—Eye disorder—Doxorubicin—lung cancer	9.78e-05	0.00024	CcSEcCtD
Maraviroc—Gastrointestinal pain—Docetaxel—lung cancer	9.74e-05	0.000239	CcSEcCtD
Maraviroc—Anaemia—Methotrexate—lung cancer	9.72e-05	0.000238	CcSEcCtD
Maraviroc—Cardiac disorder—Doxorubicin—lung cancer	9.71e-05	0.000238	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EGF—lung cancer	9.69e-05	0.000519	CbGpPWpGaD
Maraviroc—Diarrhoea—Paclitaxel—lung cancer	9.61e-05	0.000236	CcSEcCtD
Maraviroc—Angiopathy—Doxorubicin—lung cancer	9.49e-05	0.000233	CcSEcCtD
Maraviroc—Dizziness—Etoposide—lung cancer	9.48e-05	0.000232	CcSEcCtD
Maraviroc—Mediastinal disorder—Doxorubicin—lung cancer	9.43e-05	0.000231	CcSEcCtD
Maraviroc—Abdominal pain—Docetaxel—lung cancer	9.41e-05	0.000231	CcSEcCtD
Maraviroc—Body temperature increased—Docetaxel—lung cancer	9.41e-05	0.000231	CcSEcCtD
Maraviroc—Leukopenia—Methotrexate—lung cancer	9.41e-05	0.000231	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—MAPK3—lung cancer	9.39e-05	0.000503	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—POMC—lung cancer	9.33e-05	0.0005	CbGpPWpGaD
Maraviroc—Dizziness—Paclitaxel—lung cancer	9.29e-05	0.000228	CcSEcCtD
Maraviroc—Nausea—Cisplatin—lung cancer	9.29e-05	0.000228	CcSEcCtD
Maraviroc—CCR5—Disease—CDKN1A—lung cancer	9.29e-05	0.000497	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—lung cancer	9.27e-05	0.000496	CbGpPWpGaD
Maraviroc—Alopecia—Doxorubicin—lung cancer	9.24e-05	0.000227	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—BRAF—lung cancer	9.21e-05	0.000493	CbGpPWpGaD
Maraviroc—Cough—Methotrexate—lung cancer	9.18e-05	0.000225	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—lung cancer	9.17e-05	0.000225	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—POMC—lung cancer	9.16e-05	0.00049	CbGpPWpGaD
Maraviroc—Convulsion—Methotrexate—lung cancer	9.11e-05	0.000224	CcSEcCtD
Maraviroc—Vomiting—Etoposide—lung cancer	9.11e-05	0.000223	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—lung cancer	9.11e-05	0.000223	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—lung cancer	9.11e-05	0.000223	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IL6R—lung cancer	9.1e-05	0.000487	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CREBBP—lung cancer	9.09e-05	0.000487	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP2E1—lung cancer	9.08e-05	0.000486	CbGpPWpGaD
Maraviroc—Rash—Etoposide—lung cancer	9.04e-05	0.000222	CcSEcCtD
Maraviroc—Dermatitis—Etoposide—lung cancer	9.03e-05	0.000221	CcSEcCtD
Maraviroc—Headache—Etoposide—lung cancer	8.98e-05	0.00022	CcSEcCtD
Maraviroc—Flatulence—Doxorubicin—lung cancer	8.97e-05	0.00022	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2E1—lung cancer	8.96e-05	0.000479	CbGpPWpGaD
Maraviroc—Myalgia—Methotrexate—lung cancer	8.95e-05	0.00022	CcSEcCtD
Maraviroc—Vomiting—Paclitaxel—lung cancer	8.93e-05	0.000219	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—EGFR—lung cancer	8.93e-05	0.000478	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	8.89e-05	0.000218	CcSEcCtD
Maraviroc—Rash—Paclitaxel—lung cancer	8.86e-05	0.000217	CcSEcCtD
Maraviroc—Dermatitis—Paclitaxel—lung cancer	8.85e-05	0.000217	CcSEcCtD
Maraviroc—Discomfort—Methotrexate—lung cancer	8.85e-05	0.000217	CcSEcCtD
Maraviroc—CCR5—Disease—EP300—lung cancer	8.84e-05	0.000473	CbGpPWpGaD
Maraviroc—Headache—Paclitaxel—lung cancer	8.8e-05	0.000216	CcSEcCtD
Maraviroc—Hypersensitivity—Docetaxel—lung cancer	8.77e-05	0.000215	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MAP2K1—lung cancer	8.68e-05	0.000464	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CD—lung cancer	8.62e-05	0.000461	CbGpPWpGaD
Maraviroc—CCR5—Disease—SRC—lung cancer	8.6e-05	0.00046	CbGpPWpGaD
Maraviroc—Asthenia—Docetaxel—lung cancer	8.54e-05	0.00021	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—lung cancer	8.54e-05	0.000457	CbGpPWpGaD
Maraviroc—Infection—Methotrexate—lung cancer	8.53e-05	0.000209	CcSEcCtD
Maraviroc—Nausea—Etoposide—lung cancer	8.51e-05	0.000209	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—KRAS—lung cancer	8.44e-05	0.000452	CbGpPWpGaD
Maraviroc—Pruritus—Docetaxel—lung cancer	8.43e-05	0.000207	CcSEcCtD
Maraviroc—Nervous system disorder—Methotrexate—lung cancer	8.42e-05	0.000206	CcSEcCtD
Maraviroc—Anaemia—Doxorubicin—lung cancer	8.42e-05	0.000206	CcSEcCtD
Maraviroc—Nausea—Paclitaxel—lung cancer	8.35e-05	0.000205	CcSEcCtD
Maraviroc—Skin disorder—Methotrexate—lung cancer	8.34e-05	0.000204	CcSEcCtD
Maraviroc—CCR5—Disease—STAT3—lung cancer	8.29e-05	0.000444	CbGpPWpGaD
Maraviroc—CCR5—Disease—NRAS—lung cancer	8.27e-05	0.000443	CbGpPWpGaD
Maraviroc—Anorexia—Methotrexate—lung cancer	8.18e-05	0.000201	CcSEcCtD
Maraviroc—Syncope—Doxorubicin—lung cancer	8.17e-05	0.0002	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—lung cancer	8.15e-05	0.0002	CcSEcCtD
Maraviroc—Diarrhoea—Docetaxel—lung cancer	8.15e-05	0.0002	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—lung cancer	8e-05	0.000196	CcSEcCtD
Maraviroc—Cough—Doxorubicin—lung cancer	7.95e-05	0.000195	CcSEcCtD
Maraviroc—CCR5—Disease—MAPK3—lung cancer	7.92e-05	0.000424	CbGpPWpGaD
Maraviroc—Convulsion—Doxorubicin—lung cancer	7.89e-05	0.000194	CcSEcCtD
Maraviroc—Dizziness—Docetaxel—lung cancer	7.88e-05	0.000193	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methotrexate—lung cancer	7.82e-05	0.000192	CcSEcCtD
Maraviroc—Insomnia—Methotrexate—lung cancer	7.76e-05	0.00019	CcSEcCtD
Maraviroc—Myalgia—Doxorubicin—lung cancer	7.75e-05	0.00019	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—lung cancer	7.75e-05	0.000415	CbGpPWpGaD
Maraviroc—Anxiety—Doxorubicin—lung cancer	7.73e-05	0.00019	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MDM2—lung cancer	7.72e-05	0.000413	CbGpPWpGaD
Maraviroc—Paraesthesia—Methotrexate—lung cancer	7.71e-05	0.000189	CcSEcCtD
Maraviroc—CCR5—Disease—MYC—lung cancer	7.7e-05	0.000412	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	7.7e-05	0.000189	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RAF1—lung cancer	7.69e-05	0.000412	CbGpPWpGaD
Maraviroc—Discomfort—Doxorubicin—lung cancer	7.66e-05	0.000188	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ERBB2—lung cancer	7.61e-05	0.000408	CbGpPWpGaD
Maraviroc—Vomiting—Docetaxel—lung cancer	7.57e-05	0.000186	CcSEcCtD
Maraviroc—CCR5—Disease—EGFR—lung cancer	7.53e-05	0.000403	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MTOR—lung cancer	7.51e-05	0.000402	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CB—lung cancer	7.51e-05	0.000402	CbGpPWpGaD
Maraviroc—Rash—Docetaxel—lung cancer	7.51e-05	0.000184	CcSEcCtD
Maraviroc—Dermatitis—Docetaxel—lung cancer	7.5e-05	0.000184	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—lung cancer	7.49e-05	0.000401	CbGpPWpGaD
Maraviroc—Decreased appetite—Methotrexate—lung cancer	7.46e-05	0.000183	CcSEcCtD
Maraviroc—Headache—Docetaxel—lung cancer	7.46e-05	0.000183	CcSEcCtD
Maraviroc—Oedema—Doxorubicin—lung cancer	7.43e-05	0.000182	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Methotrexate—lung cancer	7.41e-05	0.000182	CcSEcCtD
Maraviroc—Fatigue—Methotrexate—lung cancer	7.4e-05	0.000182	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—lung cancer	7.39e-05	0.000395	CbGpPWpGaD
Maraviroc—Infection—Doxorubicin—lung cancer	7.38e-05	0.000181	CcSEcCtD
Maraviroc—Pain—Methotrexate—lung cancer	7.34e-05	0.00018	CcSEcCtD
Maraviroc—Shock—Doxorubicin—lung cancer	7.31e-05	0.000179	CcSEcCtD
Maraviroc—Nervous system disorder—Doxorubicin—lung cancer	7.29e-05	0.000179	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—lung cancer	7.22e-05	0.000177	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CXCL8—lung cancer	7.22e-05	0.000386	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—lung cancer	7.17e-05	0.000384	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—lung cancer	7.12e-05	0.000381	CbGpPWpGaD
Maraviroc—Anorexia—Doxorubicin—lung cancer	7.08e-05	0.000174	CcSEcCtD
Maraviroc—Nausea—Docetaxel—lung cancer	7.07e-05	0.000174	CcSEcCtD
Maraviroc—Gastrointestinal pain—Methotrexate—lung cancer	7.02e-05	0.000172	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—lung cancer	6.97e-05	0.000373	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP3—lung cancer	6.91e-05	0.00037	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—lung cancer	6.9e-05	0.000369	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—lung cancer	6.88e-05	0.000368	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—lung cancer	6.86e-05	0.000368	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	6.79e-05	0.000363	CbGpPWpGaD
Maraviroc—Abdominal pain—Methotrexate—lung cancer	6.79e-05	0.000166	CcSEcCtD
Maraviroc—Body temperature increased—Methotrexate—lung cancer	6.79e-05	0.000166	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—lung cancer	6.77e-05	0.000166	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCND1—lung cancer	6.73e-05	0.00036	CbGpPWpGaD
Maraviroc—Insomnia—Doxorubicin—lung cancer	6.72e-05	0.000165	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—JUN—lung cancer	6.71e-05	0.000359	CbGpPWpGaD
Maraviroc—Paraesthesia—Doxorubicin—lung cancer	6.67e-05	0.000164	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CA—lung cancer	6.54e-05	0.00035	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—lung cancer	6.53e-05	0.00035	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1A1—lung cancer	6.52e-05	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1A—lung cancer	6.51e-05	0.000348	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTEN—lung cancer	6.49e-05	0.000348	CbGpPWpGaD
Maraviroc—Decreased appetite—Doxorubicin—lung cancer	6.46e-05	0.000158	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	6.43e-05	0.000344	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Doxorubicin—lung cancer	6.42e-05	0.000157	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—lung cancer	6.41e-05	0.000157	CcSEcCtD
Maraviroc—Pain—Doxorubicin—lung cancer	6.36e-05	0.000156	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—lung cancer	6.36e-05	0.000156	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AKT1—lung cancer	6.33e-05	0.000339	CbGpPWpGaD
Maraviroc—Hypersensitivity—Methotrexate—lung cancer	6.32e-05	0.000155	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EP300—lung cancer	6.19e-05	0.000331	CbGpPWpGaD
Maraviroc—Asthenia—Methotrexate—lung cancer	6.16e-05	0.000151	CcSEcCtD
Maraviroc—Gastrointestinal pain—Doxorubicin—lung cancer	6.08e-05	0.000149	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—lung cancer	6.07e-05	0.000149	CcSEcCtD
Maraviroc—CCR5—Disease—HRAS—lung cancer	6.05e-05	0.000324	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SRC—lung cancer	6.02e-05	0.000322	CbGpPWpGaD
Maraviroc—Abdominal pain—Doxorubicin—lung cancer	5.88e-05	0.000144	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—lung cancer	5.88e-05	0.000144	CcSEcCtD
Maraviroc—Diarrhoea—Methotrexate—lung cancer	5.87e-05	0.000144	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—VEGFA—lung cancer	5.86e-05	0.000314	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT3—lung cancer	5.81e-05	0.000311	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NRAS—lung cancer	5.79e-05	0.00031	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—lung cancer	5.79e-05	0.00031	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—COL4A3BP—lung cancer	5.74e-05	0.000307	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AZIN2—lung cancer	5.74e-05	0.000307	CbGpPWpGaD
Maraviroc—Dizziness—Methotrexate—lung cancer	5.68e-05	0.000139	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MAPK3—lung cancer	5.55e-05	0.000297	CbGpPWpGaD
Maraviroc—Hypersensitivity—Doxorubicin—lung cancer	5.48e-05	0.000134	CcSEcCtD
Maraviroc—Vomiting—Methotrexate—lung cancer	5.46e-05	0.000134	CcSEcCtD
Maraviroc—Rash—Methotrexate—lung cancer	5.41e-05	0.000133	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—lung cancer	5.41e-05	0.000133	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MYC—lung cancer	5.39e-05	0.000289	CbGpPWpGaD
Maraviroc—Headache—Methotrexate—lung cancer	5.38e-05	0.000132	CcSEcCtD
Maraviroc—CCR5—Disease—AKT1—lung cancer	5.34e-05	0.000286	CbGpPWpGaD
Maraviroc—Asthenia—Doxorubicin—lung cancer	5.33e-05	0.000131	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EGFR—lung cancer	5.28e-05	0.000282	CbGpPWpGaD
Maraviroc—Pruritus—Doxorubicin—lung cancer	5.26e-05	0.000129	CcSEcCtD
Maraviroc—Nausea—Methotrexate—lung cancer	5.1e-05	0.000125	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—lung cancer	5.09e-05	0.000125	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KRAS—lung cancer	4.98e-05	0.000267	CbGpPWpGaD
Maraviroc—Dizziness—Doxorubicin—lung cancer	4.92e-05	0.000121	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—ATP5H—lung cancer	4.88e-05	0.000261	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—POMC—lung cancer	4.86e-05	0.00026	CbGpPWpGaD
Maraviroc—Vomiting—Doxorubicin—lung cancer	4.73e-05	0.000116	CcSEcCtD
Maraviroc—Rash—Doxorubicin—lung cancer	4.69e-05	0.000115	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—lung cancer	4.68e-05	0.000115	CcSEcCtD
Maraviroc—Headache—Doxorubicin—lung cancer	4.66e-05	0.000114	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—lung cancer	4.58e-05	0.000245	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—lung cancer	4.43e-05	0.000237	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—lung cancer	4.41e-05	0.000108	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—PLBD1—lung cancer	4.35e-05	0.000233	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HRAS—lung cancer	4.24e-05	0.000227	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—lung cancer	4.05e-05	0.000217	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSD17B10—lung cancer	3.98e-05	0.000213	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—lung cancer	3.74e-05	0.0002	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CKB—lung cancer	3.7e-05	0.000198	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CNDP2—lung cancer	3.48e-05	0.000186	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM2—lung cancer	3.48e-05	0.000186	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTMR3—lung cancer	3.38e-05	0.000181	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PGAM1—lung cancer	3.3e-05	0.000176	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2A7—lung cancer	3.14e-05	0.000168	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SDC4—lung cancer	3.08e-05	0.000165	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—RRM1—lung cancer	2.8e-05	0.00015	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA3—lung cancer	2.8e-05	0.00015	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—B4GALT5—lung cancer	2.63e-05	0.000141	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA4—lung cancer	2.56e-05	0.000137	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA2—lung cancer	2.5e-05	0.000134	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA1—lung cancer	2.41e-05	0.000129	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCC3—lung cancer	2.38e-05	0.000128	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKR1C1—lung cancer	2.31e-05	0.000124	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UGT1A1—lung cancer	2.24e-05	0.00012	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GNG11—lung cancer	2.16e-05	0.000116	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDOA—lung cancer	2.06e-05	0.00011	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA3—lung cancer	2e-05	0.000107	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ADCY1—lung cancer	1.94e-05	0.000104	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCG2—lung cancer	1.94e-05	0.000104	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPGDS—lung cancer	1.9e-05	0.000102	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ENO2—lung cancer	1.9e-05	0.000102	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.89e-05	0.000101	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTT1—lung cancer	1.85e-05	9.89e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2A6—lung cancer	1.83e-05	9.78e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GCLC—lung cancer	1.83e-05	9.78e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ENO1—lung cancer	1.73e-05	9.27e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2E1—lung cancer	1.55e-05	8.31e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NQO1—lung cancer	1.54e-05	8.22e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—STK11—lung cancer	1.38e-05	7.41e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—lung cancer	1.28e-05	6.86e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CAT—lung cancer	1.25e-05	6.67e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCB1—lung cancer	1.21e-05	6.49e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMS—lung cancer	1.19e-05	6.37e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—lung cancer	1.18e-05	6.3e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1A1—lung cancer	1.12e-05	5.97e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ERCC2—lung cancer	1.11e-05	5.92e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOA1—lung cancer	9.57e-06	5.12e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—lung cancer	8.74e-06	4.68e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—POMC—lung cancer	8.32e-06	4.45e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CREBBP—lung cancer	8.1e-06	4.34e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CD—lung cancer	7.68e-06	4.11e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—lung cancer	7.58e-06	4.06e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CB—lung cancer	6.7e-06	3.58e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—lung cancer	6.63e-06	3.55e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—lung cancer	5.79e-06	3.1e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—EP300—lung cancer	5.52e-06	2.95e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—lung cancer	4.08e-06	2.19e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—lung cancer	3.33e-06	1.79e-05	CbGpPWpGaD
